

Breast Cancer Review: A molecular Prospective on Diagnosis and Treatment

K. Haripriya*¹, K. Nandini², D.M. Mamatha³, K Swetha kumari⁴

^{1,3,4}Department of Biosciences and Sericulture, SPMVV, Tirupati

²College of Nursing, SPMVV, Tirupati

Corresponding Author:

K. Haripriya,

Department of Biosciences and Sericulture, SPMVV, Tirupati

Email ID: drjharipriya7@gmail.com

Cite this paper as: K. Haripriya, K. Nandini, D.M. Mamatha, K Swetha kumari, (2025) Breast Cancer Review: A molecular Prospective on Diagnosis and Treatment, *Journal of Neonatal Surgery*, 14 (30s), 242-250

ABSTRACT

Breast cancer remains a formidable global health challenge, affecting countless lives and necessitating the ongoing research to enhance understanding and treatment strategies. This article presents a comprehensive review of recent updates in breast cancer research, emphasizing the molecular perspective and advancements in diagnostics, treatment modalities, and personalized care approaches.

The landscape of breast cancer diagnostics has evolved significantly, with the integration of genomic profiling, liquid biopsies, and advanced imaging techniques. These innovations enable early detection, risk assessment, and the identification of molecular subtypes, thereby facilitating tailored treatment plans and improved prognoses.

Advancements in treatment modalities highlight the increasing role of targeted therapies, immunotherapies, and precision medicine. The emergence of novel drugs, coupled with an enhanced understanding of Tumor biology, offers renewed hope in mitigating drug resistance and enhancing patient outcomes.

Personalized care strategies have gained prominence, with a focus on patient-centric approaches that consider genetic, environmental, and lifestyle factors. Tailoring treatment regimens to individual patient profiles optimizes efficacy while minimizing adverse effects, leading to improved quality of life.

Furthermore, recent updates encompass the integration of multidisciplinary care models, innovative clinical trial designs, and the growing importance of patient advocacy. These elements converge to create a holistic framework that addresses not only the biological aspects of breast cancer but also the psychosocial and supportive care needs of patients.

This review delves into the dynamic landscape of breast cancer research, highlighting recent updates that span diagnostics, treatments, and patient-centred approaches. By synthesizing these advancements, this article contributes to the dissemination of knowledge and the pursuit of more effective strategies in combatting breast cancer, fostering optimism in the ongoing fight against this complex disease

Keywords: Breast Cancer, Molecular approach, Genomic profiling, Immuno therapies, Diagnosis and Treatment

1. INTRODUCTION

Breast cancer remains one of the most pressing challenges in contemporary oncology, affecting individuals worldwide and compelling the medical community to continually refine its understanding and management strategies. As the second most common cancer globally and a leading cause of cancer-related deaths among women, the significance of comprehensive and up-to-date reviews cannot be overstated. This article aims to provide a thorough and current overview of recent updates in breast cancer research, highlighting advancements in diagnostics, treatment approaches, and patient-centred care.

Over the years, extensive research efforts have enriched our comprehension of the intricate mechanisms underlying breast cancer initiation, progression, and metastasis. These insights have driven the development of innovative diagnostic tools that enable more accurate risk assessment, early detection, and precise characterization of various breast cancer subtypes. The integration of genomics, transcriptomics and proteomics has elevated the precision of diagnosis, facilitating tailored

therapeutic strategies.

In the realm of treatment, breast cancer management has evolved from a one-size-fits-all approach to a nuanced paradigm that prioritizes individualized care. Recent years have witnessed a surge in targeted therapies that specifically address the molecular modifications driving cancer growth. The advent of immunotherapies has further revolutionized treatment, harnessing the immune system's potential to combat malignancy. Additionally, advancements in surgical techniques, radiation therapies, and adjuvant treatments have contributed to improved survival rates and enhanced quality of life for breast cancer patients.

Personalized medicine has emerged as a cornerstone of breast cancer care, acknowledging the heterogeneity of the disease and tailoring interventions to patients' unique genetic profiles and treatment responses. The concept of patient-centric care extends beyond medical aspects, encompassing psychosocial support, survivorship plans, and integrative therapies that enhance overall well-being.

Moreover, a multidisciplinary approach to breast cancer management has gained prominence, recognizing the importance of collaboration among various medical specialties to provide comprehensive and holistic care. The integration of innovative clinical trial designs, real-world data analysis, and patient advocacy has further fortified the foundation of evidence-based practice.

This article embarks on a journey through the recent updates in the realm of breast cancer, aiming to synthesize the evolving landscape of research and clinical practice. By examining the strides made in diagnostics, treatment strategies and patient care, we aim to contribute to the dissemination of knowledge and the advancement of compassionate and effective breast cancer management. In the face of ongoing challenges, these updates inspire hope, illuminate progress and underscore the collective commitment to combat breast cancer with scientific rigor and empathetic care

2. HISTORY AND BACKGROUND

Breast cancer, a complex and multifaceted disease, has a storied history that spans centuries of medical observations, scientific discoveries, and evolving treatment paradigms. The journey towards understanding and managing breast cancer has been marked by pivotal moments that have reshaped medical perspectives, ignited advocacy efforts and fuelled advancements in research and clinical practice. This article delved into the historical context and background that have paved the way for recent updates in the review of breast cancer.

2.1 Early Observations and Clinical Insights:

Historical records reveal that breast cancer has been recognized for millennia, with ancient civilizations documenting the presence of breast tumours and attempting crude surgical interventions. However, it wasn't until the late 18th century that significant strides were made in understanding the disease's biology and clinical behaviour. Dr. Jean Louis Petit's observations on the spread of breast cancer to regional lymph nodes marked an early recognition of metastatic potential.

2.2 Surgical Innovations and Pathological Insights:

The 19th century witnessed pioneering efforts in surgical techniques, including the mastectomy procedure advocated by Dr. William Halsted. The development of anaesthesia and aseptic techniques paved the way for more extensive surgical interventions. The emergence of pathology as a distinct medical field furthered the understanding of breast cancer's histological characteristics and the importance of accurate diagnosis.

2.3 Radiation Therapy and Systemic Treatments:

The early 20th century introduced radiation therapy as a novel treatment modality, offering a non-surgical approach to localized disease. The advent of systemic treatments, including endocrine therapy and chemotherapy, revolutionized breast cancer management, particularly in cases of advanced disease. These developments laid the foundation for more comprehensive treatment approaches.

2.4 Identification of Hormone Receptors and Targeted Therapies:

The latter half of the 20th century marked a turning point with the discovery of estrogen and progesterone receptors in breast cancer cells. This revelation led to the development of endocrine therapies that directly targeted these receptors, ushering in a new era of targeted treatments. The late 20th century also witnessed the emergence of the human epidermal growth factor receptor 2 (HER2) as a therapeutic target, resulting in the introduction of HER2-targeted therapies.

2.5 Genomic Insights and Personalized Medicine:

Advancements in molecular biology and genomics have unlocked exceptional insights into the genetic alterations driving breast cancer. The discovery of BRCA1 and BRCA2 mutations highlighted the genetic underpinnings of hereditary breast cancer. Genomic profiling of tumors has paved the way for personalized treatment strategies, tailoring interventions to the specific molecular characteristics of each patient's cancer.

2.6 Patient Advocacy and Survivorship:

The latter part of the 20th century also witnessed the rise of breast cancer advocacy, spearheaded by courageous survivors and their supporters. This advocacy has led to increased awareness, funding for research, and improved patient care. Survivorship programs and psychosocial support have gained prominence, recognizing the holistic needs of individuals beyond medical interventions.

In conclusion, the history and background of breast cancer research and treatment exemplify a continuous journey of discovery, innovation, and compassion. Recent updates in the review of breast cancer reflect the culmination of centuries of effort and highlight the ongoing commitment to refining approaches to prevention, diagnosis, and care. This article's exploration of the historical tapestry enriches the appreciation of the strides made and the road ahead in combating breast cancer with knowledge, collaboration, and unwavering dedication.

3. CLASSIFICATION OF BREAST CANCER:

Breast cancer is a heterogeneous disease characterized by diverse molecular and histological subtypes, each with unique clinical behaviours, prognoses, and therapeutic implications. The classification of breast cancer has evolved significantly over the years, guided by advances in genomics, molecular biology, and clinical observations. This article delves into the classification of breast cancer, shedding light on recent updates that enhance our understanding of this complex disease and inform tailored treatment strategies.

3.1. Histological Subtypes:

Breast cancer can be broadly classified into several histological subtypes, including:

Ductal Carcinoma In Situ (DCIS): Early-stage cancer confined to the milk ducts (www.nationalbreastcancer.org)

Invasive Ductal Carcinoma (IDC): The most common subtype, characterized by cancer cells invading surrounding tissues.

Invasive Lobular Carcinoma (ILC): Cancer arising from the milk-producing lobules of the breast.

Mixed and Special Subtypes: Uncommon subtypes with distinct features, such as medullary, mucinous, and tubular carcinomas.

3.2. Molecular Subtypes:

Molecular classification has revolutionized breast cancer management, providing insights into tumor behavior and response to therapies. Recent updates have refined molecular subtyping, with the following key categories:

Luminal A: Estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive, HER2-negative, and low proliferation.

Luminal B: ER-positive and/or PR-positive, HER2-positive or negative, and higher proliferation.

HER2-Enriched: HER2-positive tumors, regardless of hormone receptor status.

Triple-Negative Breast Cancer (TNBC): ER-negative, PR-negative, and HER2-negative.

3.3. Genomic Profiling:

Genomic analyses have unveiled the intricate genetic landscape of breast cancer, leading to the identification of driver mutations and potential therapeutic targets. Recent updates include the integration of multigene panels and next-generation sequencing to uncover additional genetic alterations that influence tumor behavior and response to treatment.

3.4. Immunohistochemical Subtypes:

Immunohistochemical markers, including hormone receptors (ER, PR), HER2, and Ki-67 (proliferation marker), contribute to defining breast cancer subtypes. These markers guide treatment decisions and prognosis assessment.

3.5. Prognostic and Predictive Signatures:

Recent advancements involve the incorporation of gene expression signatures, such as Oncotype DX, Prosigna, and MammaPrint, into clinical practice. These tools assist in predicting recurrence risk and guiding decisions regarding adjuvant therapies.

3.6. Emerging Subtypes and Classification Updates:

Ongoing research continues to uncover novel subtypes and refine existing classifications. Subtypes based on immune cell infiltration and tumor microenvironment characteristics hold promise for enhancing treatment strategies.

In conclusion, the classification of breast cancer has evolved from simple histology to intricate molecular and genomic profiles that inform clinical decisions. Recent updates underscore the importance of tailoring treatment approaches based on these classifications, optimizing therapeutic efficacy and patient outcomes. As we navigate the ever-expanding landscape of

breast cancer subtypes, this article contributes to the dissemination of knowledge and underscores the critical role of accurate classification in the pursuit of precision medicine for breast cancer patients.

4. CAUSES OF BREAST CANCER:

Breast cancer, a complex interplay of genetic predisposition, environmental factors, and lifestyle choices, continues to be a significant global health concern. The understanding of its etiology has evolved considerably, reflecting the intricate nature of this disease. This article explores the causes of breast cancer, delving into recent updates that shed light on the multifaceted factors contributing to its development and progression.

4.1. Genetic Predisposition:

A cornerstone of breast cancer causation is genetic susceptibility. Mutations in genes such as BRCA1, BRCA2, and PALB2 substantially increase the risk of developing breast cancer. Recent updates have expanded the spectrum of genes associated with hereditary breast cancer, emphasizing the importance of genetic counselling and testing for at-risk individuals.

4.2. Hormonal Factors:

Hormones play a crucial role in breast cancer development. Early menarche, late menopause, and hormone replacement therapy (HRT) contribute to prolonged exposure to estrogen and progesterone, increasing the risk of hormone receptor-positive breast cancers. Recent updates have refined our understanding of the intricate hormonal interactions underlying breast cancer risk.

4.3. Reproductive History:

Factors such as nulliparity (state of Woman never giving birth), late age at first childbirth, and limited breastfeeding contribute to higher breast cancer risk. Conversely, early and multiple pregnancies, along with extended breastfeeding, confer protective effects. Updates highlight the dynamic relationship between reproductive choices and breast cancer risk.

4.4. Environmental Exposures:

Environmental pollutants, endocrine disruptors, and ionizing radiation have been linked to breast cancer development. Recent updates underscore the significance of minimizing exposure to these substances and monitoring their potential impact on breast health.

4.5. Lifestyle and Behavioural Factors:

Sedentary lifestyles, unhealthy dietary patterns, excessive alcohol consumption, and obesity are lifestyle factors that contribute to breast cancer risk. Emerging research emphasizes the importance of maintaining a balanced lifestyle and adopting protective behaviours.

4.6. Age and Family History:

Advancing age is a major risk factor for breast cancer, with the majority of cases occurring after the age of 50. A family history of breast cancer, especially in first-degree relatives, increases individual risk. Recent updates have identified gene-environment interactions that may modulate age-related risk.

4.7. Inflammatory and Immune Factors:

Chronic inflammation and compromised immune function have been implicated in breast cancer development. Understanding the complex interplay between the immune system and tumor microenvironment offers potential insights into preventive strategies and therapeutic interventions.

4.8. Emerging Factors and Risk Stratification:

Recent research has identified emerging risk factors, such as night-shift work and exposure to artificial light at night. Additionally, advances in risk stratification models integrate multiple factors to provide more accurate assessments of an individual's breast cancer risk.

Inferring from the above, the causes of breast cancer encompass a mosaic of genetic, hormonal, environmental, and lifestyle influences. Recent updates highlight the dynamic nature of breast cancer etiology, guiding efforts to tailor preventive strategies and personalized interventions. By shedding light on the evolving landscape of breast cancer causation, this article contributes to the dissemination of knowledge and underscores the importance of multifaceted approaches in combating this complex disease.

5. GENERAL & ADVANCED DIAGNOSIS TECHNIQUES:

The timely and accurate diagnosis of breast cancer is paramount for effective treatment and improved patient outcomes. Over the years, diagnostic techniques for breast cancer have evolved significantly, propelled by advances in medical imaging, molecular biology, and personalized medicine. This article explores the general and advanced diagnostic techniques for

breast cancer, highlighting recent updates that have revolutionized early detection and precision diagnosis.

5.1 General Diagnostic Techniques:

Clinical Breast Examination: Physicians perform physical examinations to detect palpable lumps or changes in breast tissue texture.

Mammography: X-ray imaging of breast tissue is a cornerstone of breast cancer screening, enabling the detection of early abnormalities.

Ultrasound: Ultrasound uses sound waves to visualize breast tissue, aiding in the differentiation of cysts from solid masses.

Biopsy: Tissue samples are collected for pathological examination, confirming the presence of cancer and characterizing its subtype.

5.2 Advanced Diagnostic Techniques:

Digital Mammography: Digital technology enhances the resolution and manipulation of mammographic images, improving accuracy.

Tomosynthesis (3D Mammography): This advanced mammography technique provides three-dimensional images, reducing false positives and improving detection rates.

Magnetic Resonance Imaging (MRI): MRI generates detailed images of breast tissue, particularly valuable for high-risk individuals and evaluating complex cases.

Molecular Imaging: Techniques like Positron Emission Tomography (PET) combined with computed tomography (PET-CT) provide functional and anatomical information for better staging and monitoring.

Liquid Biopsies: Analyzing blood samples for circulating tumour DNA and other biomarkers offers non-invasive monitoring of disease progression and treatment response.

Genomic Profiling: Genomic tests analyze tumour DNA to identify specific genetic alterations, guiding treatment decisions and predicting prognosis.

Gene Expression Profiling: Technologies like Oncotype DX and Mammaprint evaluate gene expression patterns, aiding in personalized treatment planning.

5.3 Precision Diagnosis and Personalized Medicine:

Recent updates emphasize the integration of molecular and genetic information into diagnostic paradigms. Molecular subtyping based on hormone receptors (ER, PR), HER2 status, and proliferation markers guide treatment selection. Genomic profiling offers insights into tumor behaviour, potential treatment response, and risk of recurrence, enabling personalized therapy strategies.

5.4 Challenges and Future Directions:

While diagnostic advancements have improved accuracy and early detection, challenges remain in optimizing sensitivity, specificity, and cost-effectiveness. Incorporating emerging technologies and machine learning algorithms may further refine diagnostic accuracy and streamline patient care.

The landscape of breast cancer diagnoses has witnessed transformative advancements, from traditional methods to cutting-edge technologies that facilitate early detection, accurate characterization, and personalized treatment strategies. Recent updates underscore the vital role of diagnostic techniques in the comprehensive management of breast cancer. By illuminating the evolving diagnostic landscape, this article contributes to the dissemination of knowledge and the pursuit of precision medicine for breast cancer patients.

5.5. GENERAL AND ADVANCED TREATMENT OPTIONS FOR BREAST CANCER

Breast cancer treatment has evolved significantly over the years, encompassing a spectrum of approaches ranging from surgery to systemic therapies. Recent updates have propelled the field forward, introducing novel strategies that enhance treatment efficacy, minimize side effects, and improve patient outcomes. This article explores the general and advanced treatment options, including chemotherapy, for breast cancer, highlighting recent updates that reflect the evolution of therapeutic interventions.

6. GENERAL TREATMENT OPTIONS:

Surgery: Surgical interventions include lumpectomy (removal of the tumor and surrounding tissue) and mastectomy (removal of the entire breast). Lymph node dissection may also be performed to assess the extent of cancer spread.

Radiation Therapy: Adjuvant or neoadjuvant radiation therapy delivers targeted high-energy beams to destroy cancer cells, reducing the risk of local recurrence.

Hormone Therapy: Hormone receptor-positive breast cancers are treated with endocrine therapies that block or suppress hormone receptors (ER, PR), reducing hormonal stimulation.

Targeted Therapies: HER2-positive breast cancers are treated with targeted therapies like trastuzumab and pertuzumab that specifically inhibit the HER2 protein.

6.1 Advanced Treatment Options:

Neoadjuvant Therapy: Administering chemotherapy or targeted therapy before surgery can shrink tumors, enabling more effective surgical resection.

Adjuvant Therapy: After surgery, adjuvant therapies such as chemotherapy, hormone therapy, and targeted therapy are used to reduce the risk of recurrence.

Immunotherapy: Immune checkpoint inhibitors are being explored for HER2-positive and triple-negative breast cancers, harnessing the immune system to fight cancer.

Precision Medicine: Genomic profiling guides the selection of targeted therapies based on the genetic characteristics of the tumor, improving treatment efficacy.

Neoadjuvant Hormone Therapy: Hormone receptor-positive tumors may respond to hormone therapy before surgery, facilitating breast-conserving surgery.

Chemotherapy:

Chemotherapy remains a cornerstone of breast cancer treatment, targeting rapidly dividing cancer cells throughout the body. Recent updates have refined chemotherapy regimens, optimizing dose and schedule to balance efficacy and minimize adverse effects. Combination therapies that combine different drugs are often used to enhance treatment outcomes.

Emerging Therapies and Personalized Approaches:

Recent advances involve the development of PARP inhibitors for BRCA-mutated breast cancers and CDK4/6 inhibitors for hormone receptor-positive tumors. Moreover, ongoing research seeks to tailor treatment approaches based on genetic mutations, biomarkers, and molecular subtypes, enabling personalized and precise interventions.

7. CHALLENGES AND FUTURE DIRECTIONS:

While treatment advances have significantly improved outcomes, challenges persist in managing treatment-related side effects, optimizing treatment sequencing, and identifying strategies for resistant tumors. Integrating emerging technologies, such as immunotherapies and gene therapies, into treatment paradigms holds promise for further enhancing therapeutic efficacy.

The landscape of breast cancer treatment has undergone remarkable evolution, offering patients a spectrum of options that reflect the complexity of the disease. Recent updates underscore the importance of tailoring treatment approaches to individual patients, optimizing efficacy while minimizing side effects. By delving into the evolving treatment landscape, this article contributes to the dissemination of knowledge and underscores the commitment to enhancing the lives of breast cancer patients through innovative and personalized therapies.

8. CURRENTLY AVAILABLE DRUGS FOR BREAST CANCER TREATMENT

Currently, a variety of drugs are available for the treatment of breast cancer, reflecting the diverse subtypes and stages of the disease. These drugs target specific molecular pathways, hormone receptors, and growth factors associated with breast cancer growth and progression. Below are some of the key classes of drugs used in breast cancer treatment:

8.1. Chemotherapy:

Chemotherapy drugs are designed to target rapidly dividing cells, including cancer cells. They are used in various stages of breast cancer treatment, including neoadjuvant (before surgery), adjuvant (after surgery), and metastatic settings. Common chemotherapy drugs used for breast cancer treatment include:

Anthracyclines: Doxorubicin (Adriamycin), epirubicin

Taxanes: Paclitaxel (Taxol), docetaxel (Taxotere)

Platinum Agents: Carboplatin, cisplatin

Cytotoxic Drugs: Cyclophosphamide, 5-fluorouracil (5-FU)

8.2. Hormone Therapy:

Hormone therapy is used for hormone receptor-positive breast cancers that depend on estrogen or progesterone for growth. It aims to block the effects of these hormones. Common hormone therapy drugs include:

Selective Estrogen Receptor Modulators (SERMs): Tamoxifen

Aromatase Inhibitors: Anastrozole, letrozole, exemestane

8.3. Targeted Therapies:

Targeted therapies specifically target molecules and pathways involved in cancer growth. These drugs are often used in conjunction with other treatments, especially for HER2-positive breast cancers. Key targeted therapies for breast cancer include:

HER2-Targeted Therapies: Trastuzumab (Herceptin), pertuzumab (Perjeta), ado-trastuzumab emtansine (Kadcyla)

CDK4/6 Inhibitors: Palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Verzenio)

PARP Inhibitors: Olaparib (Lynparza), talazoparib (Talzenna)

8.4. Immunotherapies:

Immunotherapies harness the immune system to target and destroy cancer cells. While not as commonly used in breast cancer as in other cancer types, immunotherapies are being explored for certain subtypes, such as triple-negative breast cancer. Key immunotherapy for breast cancer includes:

Immune Checkpoint Inhibitors: Pembrolizumab (Keytruda), atezolizumab (Tecentriq)

8.5. Bisphosphonates and Denosumab:

These drugs are used to prevent bone loss and fractures in breast cancer patients with bone metastases. They help strengthen bones and reduce the risk of complications.

It's important to note that treatment regimens are tailored to each individual's specific type of breast cancer, stage, and overall health. The combination of drugs and treatment modalities is determined by a multidisciplinary team of healthcare professionals, including oncologists, surgeons, and pathologists. Additionally, ongoing research continues to bring forth new drugs and treatment approaches, contributing to the evolving landscape of breast cancer therapy.

9. CONCLUSION

The journey through the recent updates on the review of breast cancer reflects the relentless pursuit of understanding, innovation, and progress in the field of oncology. With each advancement, from diagnostics to treatment options, a collective commitment emerges to redefine the landscape of breast cancer care. This article has illuminated the intricate tapestry of knowledge that shapes the lives of those affected by breast cancer, offering hope, optimism, and a renewed sense of purpose.

As we stand at the crossroads of evolving science and compassionate care, the significance of these recent updates resonates deeply. From the nuances of classification to the frontiers of personalized medicine, the intricate interplay of genetic, molecular, and environmental factors has unveiled a multi-dimensional understanding of breast cancer. Through diligent research, meticulous observation, and the dedication of healthcare professionals, the path forward becomes clearer, empowering patients with tailored interventions and improved outcomes.

The review of breast cancer extends beyond medical boundaries, encompassing emotional, psychological, and social aspects. Empowered by knowledge, patients become advocates of their own well-being, empowered to engage in shared decision-making and informed choices. Families, caregivers, and the global healthcare community rally together, united in the shared mission to transform breast cancer from a formidable adversary to a conquerable challenge.

As we reflect on the past, embrace the present, and envision the future, the importance of interdisciplinary collaboration and the integration of cutting-edge technologies becomes evident. The road ahead promises further breakthroughs, novel therapies, and enhanced survivorship. With research continuing to illuminate uncharted territories and the spirit of innovation fuelling every discovery, the horizon of breast cancer care shines brighter with hope and promise.

To conclude, the recent updates on the review of breast cancer exemplify the embodiment of medical progress, compassion, and the unwavering pursuit of excellence. By disseminating this knowledge, we contribute to a collective understanding that reaches far beyond the confines of a journal article. With hearts full of determination, we move forward, driven by the shared vision of a world where breast cancer is not just treated, but conquered, and where lives are lived to the fullest potential.

REFERENCES

- [1] Zugazagoitia, J., Guedes, C., Ponce, S., Ferrer, I., Molina-Pinelo, S., & Paz-Ares, L. (2016). Current challenges in cancer treatment. *Clinical therapeutics*, 38(7), 1551-1566.
- [2] Hassanpour, S. H., & Dehghani, M. (2017). Review of cancer from perspective of molecular. *Journal of cancer*

research and practice, 4(4), 127-129.

- [3] Litwin, M. S., & Tan, H. J. (2017). The diagnosis and treatment of prostate cancer: a review. *Jama*, 317(24), 2532-2542.
- [4] Esfahani, K., Roudaia, L., Buhlaiga, N. A., Del Rincon, S. V., Papneja, N., & Miller, W. H. (2020). A review of cancer immunotherapy: from the past, to the present, to the future. *Current Oncology*, 27(s2), 87-97.
- [5] Courneya, K. S. (2003). Exercise in cancer survivors: an overview of research. *Medicine and science in sports and exercise*, 35(11), 1846-1852.
- [6] Fass, L. (2008). Imaging and cancer: a review. *Molecular oncology*, 2(2), 115-152.
- [7] Waks, A. G., & Winer, E. P. (2019). Breast cancer treatment: a review. *Jama*, 321(3), 288-300.
- [8] Elmore, J. G., Armstrong, K., Lehman, C. D., & Fletcher, S. W. (2005). Screening for breast cancer. *Jama*, 293(10), 1245-1256.
- [9] Woo, J. C., Yu, T., & Hurd, T. C. (2003). Breast cancer in pregnancy: a literature review. *Archives of Surgery*, 138(1), 91-98.
- [10] Richie, R. C., & Swanson, J. O. (2003). Breast cancer: a review of the literature. *JOURNAL OF INSURANCE MEDICINE-NEW YORK THEN DENVER--*, 35(2), 85-101.
- [11] Waks, A. G., & Winer, E. P. (2019). Breast cancer treatment: a review. *Jama*, 321(3), 288-300.
- [12] Libson, S., & Lippman, M. (2014). A review of clinical aspects of breast cancer. *International review of psychiatry*, 26(1), 4-15.
- [13] Ronckers, C. M., Erdmann, C. A., & Land, C. E. (2004). Radiation and breast cancer: a review of current evidence. *Breast Cancer Research*, 7, 1-12.
- [14] Reich, M., Lesur, A., & Perdrizet-Chevallier, C. (2008). Depression, quality of life and breast cancer: a review of the literature. *Breast cancer research and treatment*, 110, 9-17.
- [15] Krishnamurti, U., & Silverman, J. F. (2014). HER2 in breast cancer: a review and update. *Advances in anatomic pathology*, 21(2), 100-107.
- [16] Niell, B. L., Freer, P. E., Weinfurter, R. J., Arleo, E. K., & Drukeinis, J. S. (2017). Screening for breast cancer. *Radiologic clinics*, 55(6), 1145-1162.
- [17] Matsen, C. B., & Neumayer, L. A. (2013). Breast cancer: a review for the general surgeon. *JAMA surgery*, 148(10), 971-980.
- [18] Kittaneh, M., Montero, A. J., & Glück, S. (2013). Molecular profiling for breast cancer: a comprehensive review. *Biomarkers in cancer*, 5, BIC-S9455.
- [19] Giordano, S. H. (2005). A review of the diagnosis and management of male breast cancer. *The oncologist*, 10(7), 471-479.
- [20] Hicks, D. G., & Kulkarni, S. (2008). HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. *American journal of clinical pathology*, 129(2), 263-273.
- [21] Woo, J. C., Yu, T., & Hurd, T. C. (2003). Breast cancer in pregnancy: a literature review. *Archives of Surgery*, 138(1), 91-98.
- [22] Xue, F., & Michels, K. B. (2007). Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. *The American journal of clinical nutrition*, 86(3), 823S-835S.
- [23] Fann, J. R., Thomas-Rich, A. M., Katon, W. J., Cowley, D., Pepping, M., McGregor, B. A., & Gralow, J. (2008). Major depression after breast cancer: a review of epidemiology and treatment. *General hospital psychiatry*, 30(2), 112-126.
- [24] Ann Bettencourt, B., Schlegel, R. J., Talley, A. E., & Molix, L. A. (2007). The breast cancer experience of rural women: a literature review. *Psycho-Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer*, 16(10), 875-887.
- [25] Becker, S. (2015). A historic and scientific review of breast cancer: The next global healthcare challenge. *International Journal of Gynecology & Obstetrics*, 131, S36-S39.
- [26] Sun, L., Legood, R., dos-Santos-Silva, I., Gaiha, S. M., & Sadique, Z. (2018). Global treatment costs of breast cancer by stage: a systematic review. *PloS one*, 13(11), e0207993.
- [27] Maman, S., & Witz, I. P. (2018). A history of exploring cancer in context. *Nature Reviews Cancer*, 18(6), 359-376.
- [28] Murff, H. J., Spigel, D. R., & Syngal, S. (2004). Does this patient have a family history of cancer?: an evidence-

based analysis of the accuracy of family cancer history. *Jama*, 292(12), 1480-1489.

- [29] Sudhakar, A. (2009). History of cancer, ancient and modern treatment methods. *Journal of cancer science & therapy*, 1(2), 1.
- [30] Hajdu, S. I. (2011). A note from history: landmarks in history of cancer, part 1. *Cancer*, 117(5), 1097-1102.
- [31] DeVita Jr, V. T., & Chu, E. (2008). A history of cancer chemotherapy. *Cancer research*, 68(21), 8643-8653.
- [32] Zhang, Y., & Zhang, Z. (2020). The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. *Cellular & molecular immunology*, 17(8), 807-821.
- [33] Esfahani, K., Roudaia, L., Buhlaiga, N. A., Del Rincon, S. V., Papneja, N., & Miller, W. H. (2020). A review of cancer immunotherapy: from the past, to the present, to the future. *Current Oncology*, 27(s2), 87-97.
- [34] Chuang, H. Y., Lee, E., Liu, Y. T., Lee, D., & Ideker, T. (2007). Network-based classification of breast cancer metastasis. *Molecular systems biology*, 3(1), 140.
- [35] Araújo, T., Aresta, G., Castro, E., Rouco, J., Aguiar, P., Eloy, C., ... & Campilho, A. (2017). Classification of breast cancer histology images using convolutional neural networks. *PloS one*, 12(6), e0177544.
- [36] Malhotra, G. K., Zhao, X., Band, H., & Band, V. (2010). Histological, molecular and functional subtypes of breast cancers. *Cancer biology & therapy*, 10(10), 955-960.
- [37] Dai, X., Cheng, H., Bai, Z., & Li, J. (2017). Breast cancer cell line classification and its relevance with breast tumor subtyping. *Journal of Cancer*, 8(16), 3131.
- [38] Key, T. J., Verkasalo, P. K., & Banks, E. (2001). Epidemiology of breast cancer. *The lancet oncology*, 2(3), 133-140.
- [39] Akram, M., Iqbal, M., Daniyal, M., & Khan, A. U. (2017). Awareness and current knowledge of breast cancer. *Biological research*, 50, 1-23.
- [40] Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., & Boyle, P. (2003). Overview of the main outcomes in breast-cancer prevention trials. *The Lancet*, 361(9354), 296-300.
- [41] Kroenke, C. H., Chen, W. Y., Rosner, B., & Holmes, M. D. (2005). Weight, weight gain, and survival after breast cancer diagnosis. *Journal of clinical oncology*, 23(7), 1370-1378.
- [42] Unger-Saldaña, K. (2014). Challenges to the early diagnosis and treatment of breast cancer in developing countries. *World journal of clinical oncology*, 5(3), 465.
- [43] Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016). Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. *Nature reviews Clinical oncology*, 13(11), 674-690.
- [44] Rivenbark, A. G., O'Connor, S. M., & Coleman, W. B. (2013). Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. *The American journal of pathology*, 183(4), 1113-1124